Pharmacological Advances in the Treatment of Alzheimer’s Disease

Volume 2 - Issue 1

José Guedes da Silva junior*

Received: August 09, 2019;   Published: August 16, 2019

DOI: 10.32474/GJAPM.2019.02.000127

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Alzheimer’s disease is a disease that is associated with an increase in beta-amyloid peptide that accumulates in amyloid plaques found in multiple areas of the brain, such as the cerebral cortex, hippocampus, basal ganglia, thalamus, and cerebellum. One of the major genetic risks for the development of this disease is associated with the malfunction of Apoliprotein E (Apo-E), a protein whose performance ultimately causes the degradation of Beta amyloid. This neurodegenerative disease is an increasingly common problem due to the increasing aging of the world population and estimates are tripling by 2050 the number of people with Alzheimer’s in the world.

Introduction| References|